European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Retrieved on:
星期四, 九月 7, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, MSD, Vaccination, Chills, Public, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Ebola, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, EC, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus
The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
Key Points:
- The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
- “Ebola virus disease is severe and potentially life-threatening for both children and adults.
- INDICATIONS AND USAGE IN THE U.S.
ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. - Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.